Skip to main content
Listen in: the latest news on GLP-1s! Listen to our new Coffee with ClearScript for the latest news on GLP-1s!

The clear choice in pharmacy benefit management.

Insights Archive

April 3, 2024

Rezdiffra (resmetirom)

On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.

Looking down at a heart-shaped bowl of fruits, vegetables and nuts held in hands. Behind the bowl, slightly out of focus, is a medical clipboard with stethoscope and diabetes devices.

January 11, 2024

New Drug Spotlight: Zepbound

On November 8, 2023, Eli Lilly announced the approval of the newest weight loss drug Zepbound, a much-anticipated formulation of tirzepatide in the high-profile GLP-1 agonist medications class. Used along with reduced calorie diet and exercise, studies have shown Zepbound can lead to significant weight loss.

bottle of spilled pills

October 2, 2023

New Drug Spotlight: Arexvy, Abrysvo, and Beyfortus

In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.

bottle of spilled pills

May 30, 2023

New Drug Spotlight: Amjevita

The launch of Amjevita, the first FDA-approved biosimilar for Humira, is big news for pharmacy benefit plan sponsors.